• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Society of Nephrology - Kidney Week 2024

October 23 - 27, 2024

  1. LOKELMA (Sodium zirconium cyclosilicate)
  2. Chronic Kidney Disease
  3. Albuminuria
  4. FARXIGA (dapagliflozin)

pdf

Hyperkalemia-Related HRU Associated with Short-Term vs. Long-Term SZC Therapy in Patients with ESKD: The GALVANIZE Outcome study

pdf

Updated Design and Status of CONTINUITY: a Phase 4 Study of Continued Post-Discharge Sodium Zirconium Cyclosilicate in CKD

PDF

Effects of 3.0 mEq/L [K+] Dialysate with Sodium Zirconium Cyclosilicate (SZC) Versus 2.0 mEq/L [K+] Dialysate Without SZC on Cardiac Arrhythmia Rates

pdf

Hyperkalemia Treatment Strategies by Specialty in the TRACK Study: Interim Analysis

pdf

Evaluating the Clinical, Socioeconomic, and Environmental Impact of Guideline-directed Therapy in the US: an IMPACT CKD Analysis

html

Pediatric and Adult Kidneys Have Largely Similar Gene Expression in CKD and Non-CKD

html

Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD

html

Application of eGFR Thresholds as End Point Components in a Kidney Hierarchical Composite End Point

html

A Phase 2b Dose-Finding Study to Evaluate Effects of Balcinrenone/Dapagliflozin vs. Dapagliflozin in Patients With CKD and Albuminuria

PDF

Effect of Baxdrostat on Albuminuria in Treatment-resistant Hypertension

html

Effects of Dapagliflozin on Sodium Excretion and Blood Pressure in Patients with Type 2 Diabetes and CKD during Standardized Sodium Intake

html

Benefits of Dapagliflozin in Slowing eGFR Decline in Patients With Different Rates of eGFR Loss

html

Differences in Plasma Proteomic Profiles Between Patients With and Without Type 2 Diabetes and Chronic Kidney Disease: New Insights From DAPA-CKD

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice